Autolus Therapeutics plc Deferred Costs, Current
Autolus Therapeutics plc (AUTL) had Deferred Costs, Current of $2.24 million as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredCostsCurrent · last filed 2024-11-12
- 2024-09-30: Deferred Costs, Current $2.24M.
- 2024-06-30: Deferred Costs, Current $1.78M.
- 2024-03-31: Deferred Costs, Current $1.66M.
- 2023-12-31: Deferred Costs, Current $1.79M.
| Period end | Deferred Costs, Current |
|---|---|
| 2024-09-30 | $2.24M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.78M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.66M 10-Q · filed 2024-05-17 |
| 2023-12-31 | $1.79M 10-Q · filed 2024-11-12 |
| 2023-09-30 | $1.91M 10-Q · filed 2023-11-09 |
| 2022-12-31 | $1.49M 10-Q · filed 2023-11-09 |
| 2021-03-31 | $1.55M 6-K · filed 2021-05-06 |
| 2020-12-31 | $3.01M 6-K · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |